A Phase 1 interventional study of Placebo and PF-06835919 in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-06.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Pfizer.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2017, is one of 9 in phase 1, and was the 4th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 48 across the 15 interventional studies, 120 across the 1 observational. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Part A will investigate the safety, tolerability, PK and PD of PF-06835919 administered for 14 days in a multiple ascending dose design. Part B will assess the effect of PF-06835919 co-administration at low and high doses on the PK of atorvastatin in a single cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablets administered once or twice daily, with food, in Part A for 14 days.
Drug: Placebo
Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
Drug: PF-06835919 · Drug: atorvastatin
In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
Drug: PF-06835919 · Drug: atorvastatin
Tablets administered once or twice daily, with food, in Part A.
Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Part A
Time frame: Screening to Day 24
Number of Participants With Clinical Laboratory Abnormalities
Part A
Time frame: Day -2 to Day 24
Change from baseline in vital signs
Part A
Time frame: Day -1 to Day 24
Change from baseline in 12-lead electrocardiogram
Part A
Time frame: Day -1 to Day 24
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day -1 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day 3 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) on Day 7 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day -1 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day 3 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) on Day 7 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 3 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Maximum Observed Plasma Concentration (Cmax) on Day -1 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Maximum Observed Plasma Concentration (Cmax) on Day 3 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Maximum Observed Plasma Concentration (Cmax) on Day 7 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Plasma Decay Half-Life (t1/2) on Day -1 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Plasma Decay Half-Life (t1/2) on Day 3 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Plasma Decay Half-Life (t1/2) on Day 7 of atorvastatin and 2 active metabolites
Part B
Time frame: 0,0.5,1,1.5,2,3,4,6,9,12,24,36 and 48 hours post-atorvastatin dose
Maximum Observed Plasma Concentration (Cmax) on Day 1 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Maximum Observed Plasma Concentration (Cmax) on Day 7 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Maximum Observed Plasma Concentration (Cmax) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48, and 72 hours post-dose
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 1 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Apparent Oral Clearance (CL/F) on Day 7 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Apparent Oral Clearance (CL/F) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Minimum Observed Plasma Trough Concentration (Cmin) on Day 7 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Minimum Observed Plasma Trough Concentration (Cmin) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Accumulation Ratio (Rac) on Day 7 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Accumulation Ratio (Rac) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) on Day 7 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Accumulation Ratio for Maximum Observed Plasma Concentration (Rac,Cmax) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Plasma Decay Half-Life (t1/2) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Apparent Volume of Distribution (Vz/F) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Cumulative Amount of Drug Recovered Unchanged in Urine (Ae) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Percent Cumulative Amount of Drug Recovered Unchanged in Urine (Ae%) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Renal Clearance (CLr) on Day 14 Part A
Time frame: 0,0.5,1,2,4,5,6,8,12,14,16,24,36,48 and 72 hours post-dose
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Part B
Time frame: Screening to Day 18
Number of Participants With Clinical Laboratory Abnormalities
Part B
Time frame: Day -2 to Day 18
Change from Baseline in Vital Signs
Part B
Time frame: Day -2 to Day 18
Change from baseline in 12-lead electrocardiogram
Part B
Time frame: Day -2 to Day 18
Area Under the Curve from Time Zero to end of dosing interval (AUCtau) on Day 7 Part A
Time frame: 0,0.5,1,2,4,5,6,8 and 12 hours post-dose
Plan to share: No — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Ran from Jan 2017 to primary completion in Jul 2017, 6 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 6 months is below that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PF-06835919 · Atorvastatin
Non-alcoholic Fatty Liver Disease →